Myriad Genetics Reports Third Quarter Financial Results November 1, 2022 Click here for presentation. Highlights: Revenue of $156.4 million for the quarter ended September 30, 2022. Third quarter revenue, excluding div... Continue Reading
Myriad Genetics to Release 2022 Third-Quarter Financial Results on Nov. 1, 2022 October 26, 2022 Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third-quarter earnings conference call on Tuesday, Nov.... Continue Reading
Family Cancer History Still a Mystery to Many Women September 28, 2022 Results from a nationwide survey conducted on the attitudes, knowledge, and practices related to risk assessment, prevention, and screening for breast and ovari... Continue Reading
Myriad Genetics Reports Second Quarter Financial Results August 4, 2022 Highlights: Revenue of $179.3 million for the quarter ended June 30, 2022 Excluding revenue from divested businesses, revenue increased 7% year-over-year an... Continue Reading
Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022 July 28, 2022 Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second-quarter earnings conference call on Thursday, Au... Continue Reading
Myriad Genetics to Share Update on Business Transformation, Research and Development Pipeline, and Growth Plans at Investor Day on Aug. 11, 2022 July 19, 2022 Myriad Genetics, Inc., (NASDAQ: MYGN), will host an Investor Day on Aug. 11, 2022, providing a strategic business update and overview of the company’s growth ... Continue Reading
Access to Myriad Genetics’ GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial July 12, 2022 Study showed PGx testing helps clinicians prescribe fewer medications with gene-drug interactions Major Depressive Disorder (MDD) remission rates were signif... Continue Reading